Jordan McInerney Appointed as Chief Development Officer of The Oncology Institute
April 08 2024 - 8:00AM
The Oncology Institute, Inc. and its affiliates (NASDAQ: TOI) is
pleased to announce the appointment of Jordan McInerney as the new
Chief Development Officer (CDO), effective April 1, 2024. In this
role, Mr. McInerney will spearhead growth initiatives for The
Oncology Institute across diverse markets, including cultivating
new partnerships with payors, driving M&A processes for
acquisition targets, and establishing MSO platforms to deliver
value-based oncology care nationwide.
Bringing over 15 years of healthcare leadership, McInerney most
recently served as the Chief Operations Officer of HOPCo Network
Solutions, a subsidiary of Healthcare Outcomes Performance Co.
(HOPCo). Here, he oversaw the operations and expansion of
musculoskeletal capitation networks. His tenure at HOPCo
encompassed various executive positions, including Executive Vice
President of Growth & Network Strategies and Executive Vice
President of Value Based Care. Notably, Mclnerney played a pivotal
role in business development, strategic partnerships, and
facilitating acquisitions. Prior to his time at HOPCo, he held
various sales and operations leadership roles at Stryker, where he
focused on value-based care solutions, customer alignment
strategies and business development.
"We are delighted to welcome Jordan McInerney to The Oncology
Institute as our new Chief Development Officer," stated Dr. Daniel
Virnich, Chief Executive Officer at The Oncology Institute. "His
extensive expertise in value-based care and strategic business
development will be invaluable as we advance our mission of
providing exceptional cancer care nationwide. We are confident that
Jordan's leadership will propel sustained growth and success for
TOI."
Mr. McInerney's appointment reflects The Oncology Institute's
commitment to strategic growth and innovation.
"I am deeply honored to join The Oncology Institute and to
spearhead development efforts for such a remarkable organization
dedicated to advancing value-based cancer care," expressed
McInerney. "I eagerly anticipate collaborating with the talented
team at The Oncology Institute to drive innovation, broaden our
impact, and ultimately improve outcomes for cancer patients."
About The Oncology Institute
Founded in 2007, The Oncology Institute, Inc. and its affiliates
(NASDAQ: TOI) is advancing oncology by delivering highly
specialized, value-based cancer care in the community setting. TOI
offers cutting-edge, evidence-based cancer care to a population of
more than 1.8 million patients including clinical trials,
transfusions, and other care delivery models traditionally
associated with the most advanced care delivery organizations. With
110+ employed clinicians and over 70 clinic locations and growing,
TOI is changing oncology for the better. For more information visit
www.theoncologyinstitute.com.
Contacts
Investors at Solebury Strategic Communications
investors@theoncologyinstitute.com
Oncology Institute (NASDAQ:TOI)
Historical Stock Chart
From Jul 2024 to Aug 2024
Oncology Institute (NASDAQ:TOI)
Historical Stock Chart
From Aug 2023 to Aug 2024